Ajanta Pharma Limited (BOM:532331)
India · Delayed Price · Currency is INR 2,716.95
+2.65 (0.10%)
At close: Jan 22, 2026
Ajanta Pharma Revenue
Ajanta Pharma had revenue of 13.54B INR in the quarter ending September 30, 2025, with 14.08% growth. This brings the company's revenue in the last twelve months to 49.73B, up 10.74% year-over-year. In the fiscal year ending March 31, 2025, Ajanta Pharma had annual revenue of 46.48B with 10.44% growth.
Revenue (ttm)
49.73B
Revenue Growth
+10.74%
P/S Ratio
6.78
Revenue / Employee
5.17M
Employees
9,628
Market Cap
337.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 46.48B | 4.39B | 10.44% |
| Mar 31, 2024 | 42.09B | 4.66B | 12.45% |
| Mar 31, 2023 | 37.43B | 4.02B | 12.02% |
| Mar 31, 2022 | 33.41B | 4.51B | 15.62% |
| Mar 31, 2021 | 28.90B | 3.02B | 11.66% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dr. Reddy's Laboratories | 342.15B |
| Lupin | 247.51B |
| Jubilant Pharmova | 76.18B |
| Abbott India | 67.14B |
| Granules India | 48.42B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| GlaxoSmithKline Pharmaceuticals | 37.09B |
| Caplin Point Laboratories | 20.42B |
Ajanta Pharma News
- 11 days ago - India’s Ajanta Pharma eyes Irish manufacturing base - Independent Ireland
- 4 weeks ago - Ajanta Pharma shares jump over 4% after signing in-licensing agreement with Biocon - Business Upturn
- 4 weeks ago - Biocon signs out-licensing deal with Ajanta Pharma to market Semaglutide in overseas markets - Business Upturn
- 2 months ago - Bharti Airtel, Titan & more: Top stocks on brokers' radar today - The Times of India
- 2 months ago - Ajanta Pharma Ltd (BOM:532331) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ... - GuruFocus
- 2 months ago - Q2 2026 Ajanta Pharma Ltd Earnings Call Transcript - GuruFocus
- 3 months ago - Ajanta Pharma to consider interim dividend for FY26 at November 3 board meeting; record date set for November 10 - Business Upturn
- 5 months ago - Top stocks to watch today, August 21: Godrej Properties, RailTel, Ajanta Pharma, India Cements and more - Business Upturn